The United Laboratories International Holdings Limited (3933.HK)
HKD 13.68
(1.03%)
HKD 13.68
(1.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.04 Billion CNY | 3.19% |
| 2022 | 2.95 Billion CNY | -2.63% |
| 2021 | 3.03 Billion CNY | 6.15% |
| 2020 | 2.85 Billion CNY | 11.98% |
| 2019 | 2.54 Billion CNY | 25.37% |
| 2018 | 2.03 Billion CNY | -7.08% |
| 2017 | 2.18 Billion CNY | 4.96% |
| 2016 | 2.08 Billion CNY | 2.87% |
| 2015 | 2.02 Billion CNY | 13.94% |
| 2014 | 1.77 Billion CNY | 46.04% |
| 2013 | 1.21 Billion CNY | -11.65% |
| 2012 | 1.37 Billion CNY | 12.19% |
| 2011 | 1.22 Billion CNY | 9.85% |
| 2010 | 1.11 Billion CNY | 23.13% |
| 2009 | 908.76 Million CNY | 32.34% |
| 2008 | 686.69 Million CNY | 29.17% |
| 2007 | 531.61 Million CNY | 21.9% |
| 2006 | 436.09 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.54 Billion CNY | 0.0% |
| 2023 Q2 | 1.61 Billion CNY | 0.0% |
| 2023 Q4 | 1.43 Billion CNY | 0.0% |
| 2023 FY | 3.04 Billion CNY | 3.19% |
| 2022 Q2 | 1.43 Billion CNY | 0.0% |
| 2022 Q4 | 1.51 Billion CNY | 0.0% |
| 2022 FY | 2.95 Billion CNY | -2.63% |
| 2021 FY | 3.03 Billion CNY | 6.15% |
| 2021 Q4 | 1.65 Billion CNY | 0.0% |
| 2021 Q2 | 1.37 Billion CNY | 0.0% |
| 2020 FY | 2.85 Billion CNY | 11.98% |
| 2020 Q2 | 1.4 Billion CNY | 0.0% |
| 2020 Q4 | 1.45 Billion CNY | 0.0% |
| 2019 Q2 | 1.26 Billion CNY | 0.0% |
| 2019 Q4 | 1.28 Billion CNY | 0.0% |
| 2019 FY | 2.54 Billion CNY | 25.37% |
| 2018 Q2 | 1.32 Billion CNY | 0.0% |
| 2018 Q4 | 711.54 Million CNY | 0.0% |
| 2018 FY | 2.03 Billion CNY | -7.08% |
| 2017 FY | 2.18 Billion CNY | 4.96% |
| 2017 Q2 | 908.73 Million CNY | 0.0% |
| 2017 Q4 | 1.28 Billion CNY | 0.0% |
| 2016 Q4 | 1.19 Billion CNY | 0.0% |
| 2016 Q2 | 889.39 Million CNY | 0.0% |
| 2016 FY | 2.08 Billion CNY | 2.87% |
| 2015 Q4 | 1 Billion CNY | 0.0% |
| 2015 FY | 2.02 Billion CNY | 13.94% |
| 2015 Q2 | 978.7 Million CNY | 0.0% |
| 2014 FY | 1.77 Billion CNY | 46.04% |
| 2014 Q4 | 1.29 Billion CNY | 0.0% |
| 2014 Q2 | 482.22 Million CNY | 0.0% |
| 2013 Q4 | 450.32 Million CNY | 0.0% |
| 2013 Q2 | 778.93 Million CNY | 0.0% |
| 2013 FY | 1.21 Billion CNY | -11.65% |
| 2012 Q3 | 344.74 Million CNY | 0.0% |
| 2012 FY | 1.37 Billion CNY | 12.19% |
| 2012 Q4 | 366.28 Million CNY | 6.25% |
| 2012 Q1 | 344.74 Million CNY | 0.0% |
| 2012 Q2 | 344.74 Million CNY | 0.0% |
| 2011 Q1 | 22.3 Million CNY | 0.0% |
| 2011 FY | 1.22 Billion CNY | 9.85% |
| 2011 Q4 | 344.74 Million CNY | 1445.33% |
| 2011 Q3 | 22.3 Million CNY | 0.0% |
| 2011 Q2 | 22.3 Million CNY | 0.0% |
| 2010 Q1 | 2.97 Million CNY | 0.0% |
| 2010 FY | 1.11 Billion CNY | 23.13% |
| 2010 Q4 | 22.3 Million CNY | 650.75% |
| 2010 Q3 | 2.97 Million CNY | 0.0% |
| 2010 Q2 | 2.97 Million CNY | 0.0% |
| 2009 Q3 | 4.96 Million CNY | 0.0% |
| 2009 Q2 | 4.96 Million CNY | 0.0% |
| 2009 Q1 | 4.96 Million CNY | 0.0% |
| 2009 FY | 908.76 Million CNY | 32.34% |
| 2009 Q4 | 2.97 Million CNY | -40.14% |
| 2008 FY | 686.69 Million CNY | 29.17% |
| 2008 Q4 | 4.96 Million CNY | 201.81% |
| 2008 Q3 | -4.87 Million CNY | 0.0% |
| 2008 Q1 | -4.87 Million CNY | 0.0% |
| 2008 Q2 | -4.87 Million CNY | 0.0% |
| 2007 Q2 | 2.96 Million CNY | 0.0% |
| 2007 Q1 | 2.96 Million CNY | 0.0% |
| 2007 FY | 531.61 Million CNY | 21.9% |
| 2007 Q4 | -4.87 Million CNY | -264.18% |
| 2007 Q3 | 2.96 Million CNY | 0.0% |
| 2006 Q4 | 2.96 Million CNY | -57.49% |
| 2006 Q3 | 6.98 Million CNY | 0.0% |
| 2006 Q1 | 6.98 Million CNY | 0.0% |
| 2006 FY | 436.09 Million CNY | 0.0% |
| 2006 Q2 | 6.98 Million CNY | 0.0% |
| 2005 Q4 | 6.98 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -12369.366% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 21.114% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -8472.404% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -760.479% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -17707.964% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -415.323% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | -147.812% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -504.914% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -1305.868% |
| SSY Group Limited | 1.98 Billion HKD | -53.757% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -1758.428% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -959.867% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 89.625% |